Lucila Garcia-Contreras, Ph.D.

---

Summary

The research goal of my laboratory is “Targeted Drug Delivery” and involves the rational design of dosage forms and their in vitro evaluation, which are used to design in vivo studies. In turn, the information obtained in in vitro and in vivo studies is used to understand the underlying reasons of the performance of the dosage form with the objective of improving its formulation design to achieve the desired therapeutic effect. 

   A recent project that illustrates this process is the formulation of a novel molecule with anticancer and antimicrobial activity for pulmonary delivery as nanocrystals or microparticles. In vitro evaluation included size analysis using Scanning Electron Microscopy (SEM) and laser diffraction; stability, using (Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and differential scanning calorimetry (DSC). We determined the aerosol performance of these formulations using commercial dry powder inhalers and performed pharmacokinetic studies to determine the disposition of the drug after pulmonary administration to mice. Lastly, in collaboration with Dr. Jie Wu from the OUHSC Department of Pathology, we assessed the efficacy of the nanocrystals in a transgenic mouse model of adenocarcinoma.

   My laboratory also designs dosage forms for oral, vaginal and transdermal administration following same procedure.  A second line of investigation of my laboratory is the development of needle-less vaccines to provide mucosal and systemic immunization. We are interested in elucidating the role of cell mediated immune (CMI) response and humoral immunity to the overall protection provided by the vaccine. Examples of vaccines studied in my laboratory include vaccines against tuberculosis, West Nile Virus, Diphtheria and Shigellosis.

---

Publications & Presentations

11. Bourlon M, Garcia-Contreras L. OHet72 and Current Tuberculosis Treatments: Identifying Synergy. The Interdisciplinary Student Council through the Office of Interdisciplinary Programs. 2023

12. Beathard A, Garcia-Contreras L. Optimization of Aerosol Administration of OHet72 Nanosuspensions for Tuberculosis Treatment. The Interdisciplinary Student Council through the Office of Interdisciplinary Programs. 2023

13. Beathard A, Garcia-Contreras L. Aerosol Administration of OHet72 Nanosuspensions for Tuberculosis Treatment. 10th Annual OCRID Research Retreat, , April 11th, 2023. 2023

14. Bourlon M, Garcia-Contreras L. Identifying Synergistic Drug Interactions with OHet72: A Promising New Tuberculosis Treatment. Graduate Research Education and Technology (GREAT) symposium. 2023

15. Beathard A, Garcia-Contreras L. Optimization of Aerosol Administration of OHet72 Nanosuspensions for Tuberculosis Treatment. Graduate Research Education and Technology (GREAT) symposium. 2023

Grants

6. Preclinical Assessment of OHet72 as a new drug in the armamentarium against TB and MDR-TB. NIH. Start Date: 2019. End Date: 2021.

7. Ovarian Cancer Chemoprevention. NIH. Start Date: 2015. End Date: 2020.

8. “Inhaled Delivery of Clofazimine (CFZ) – A high efficiency, flow independent, targeted, low cost DPI. NIH. Start Date: 2018. End Date: 2020.

9. OHet72: A potential new drug in the armamentarium against TB and MDR-TB”. NIH. Start Date: 2018. End Date: 2019.

10. Preclinical studies and preliminary toxicology studies to support and Exploratory IND application for the use of vaginal suppositories containing SHetA2 for the treatment of cervical dysplasia. Misc Non-Federal. Start Date: 2017. End Date: 2018.

Awards and Honors

6. National Autonomous University of Mexico. Gabino Barreda Medal-UNAM. Date: 1991.

Education

1. Degree: Post doctoral education. the University of North Carolina at Chapel Hill. Date: 2001.


2. Degree: Ph D. The University of Georgia. Date: 1999.


3. Degree: MS. The University of Georgia. Date: 1995.


4. Degree: Chemist Pharmacist Biologist. National Autonomous University of Mexico. Date: 1991.

Administrative Assignments

no results